Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 3

Valproate-associated reversible encephalopathy in a 3-year-old girl with Pallister-Killian syndrome

Authors Gerstner T, Bell N, Koenig SA

Published 6 June 2008 Volume 2008:4(3) Pages 645—647

DOI https://doi.org/10.2147/TCRM.S2570

Thorsten Gerstner, Nellie Bell, Stephan A Koenig

University Children’s Hospital, Mannheim, Germany

Abstract: Valproic acid (VPA) is considered to be a drug of first choice for the therapy of generalized and focal epilepsies, including special epileptic syndromes. The drug is usually well tolerated, rare serious complications may occur in some patients, including hemorrhagic pancreatitis, coagulapathies, bone marrow suppression, VPA-induced hepatotoxicity and encephalopathy. We report a case of VPA-associated encephalopathy without hyperammonemia in a 3-year-old girl with Pallister-Killian-Syndrom, combined with a mild hepatopathy and thrombopathy. After withdrawal of VPA, the clinical symptoms and the electroencephalography-alterations vanished rapidly.

Keywords: pallister-killian, valproate, encephalopathy, EEG, ammonia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

In vitro cytotoxicity of the ternary PAMAM G3–pyridoxal–biotin bioconjugate

Uram Ł, Szuster M, Gargasz K, Filipowicz A, Wałajtys-Rode E, Wołowiec S

International Journal of Nanomedicine 2013, 8:4707-4720

Published Date: 11 December 2013

Use of ibandronate in the prevention of skeletal events in metastatic breast cancer

Bianca Devitt, Sue-Anne McLachlan

Therapeutics and Clinical Risk Management 2008, 4:453-458

Published Date: 11 April 2008

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma

Gennaro D’Amato, Antonello Salzillo. Amedeo Piccolo, Maria D’Amato, Gennaro Liccardi

Therapeutics and Clinical Risk Management 2007, 3:613-619

Published Date: 15 September 2007

Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors

Jean-Pierre Armand, Vincent Ribrag, Jean-Luc Harrousseau, Lauren Abrey

Therapeutics and Clinical Risk Management 2007, 3:213-224

Published Date: 15 May 2007

Comparison of echinocandin antifungals

Gregory Eschenauer, Daryl D DePestel, Peggy L Carver

Therapeutics and Clinical Risk Management 2007, 3:71-97

Published Date: 15 March 2007